This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Pfizer (PFE) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis
by Zacks Equity Research
European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
by Kinjel Shah
FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.
The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer
by Zacks Equity Research
Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
by Kinjel Shah
Both JNJ & PFE expect their sales and profits to improve in 2025.
Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
by Kinjel Shah
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
by Zacks Equity Research
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
by Zacks Equity Research
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Here's Why Pfizer (PFE) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
5 Large Drug Stocks to Watch as Industry Recovers
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
by Tirthankar Chakraborty
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
J&J to Invest $55B in United States to Boost Manufacturing, R&D
by Zacks Equity Research
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
by Kinjel Shah
Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.
GILD Stock Down on Report of Cut in HIV Prevention Spending
by Zacks Equity Research
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
by Zacks Equity Research
Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.
Pfizer (PFE) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Pfizer (PFE) closed at $26.21 in the latest trading session, marking a -0.38% move from the prior day.
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.